What Does Neurimmune AG Do?

Total employees65
HeadquartersSchlieren
Founded2006

Neurimmune is a Swiss biopharmaceutical company focused on the discovery and development of novel human-derived therapeutic antibodies for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and frontotemporal dementia. The company leverages its proprietary Reverse Translational Medicine™ (RTM™) technology platform, which identifies therapeutic candidates by analyzing the human immune system's response to disease. Neurimmune has a pipeline of promising drug candidates and has established significant collaborations with major pharmaceutical companies to advance its innovative therapies.

Where Is Neurimmune AG's Headquarters?

HQ Function

Serves as the primary center for research and development, corporate operations, and strategic decision-making.

Notable Features:

Located within the Bio-Technopark Schlieren-Zürich, a leading Swiss innovation hub for life sciences, providing state-of-the-art laboratory and office facilities.

Work Culture:

Characterized by a strong emphasis on scientific innovation, collaboration, precision, and a patient-driven mission to combat neurodegenerative diseases.

HQ Significance:

Strategically positioned in a major European biotechnology cluster, offering access to a skilled talent pool, research institutions, and global connectivity.

Values Reflected in HQ: The headquarters' focus on cutting-edge research reflects Neurimmune's commitment to innovation, scientific excellence, and translational medicine.

Location:

While Neurimmune's primary operations are centralized at its headquarters in Switzerland, its global presence is established through international collaborations with pharmaceutical partners, clinical trials conducted across multiple countries, and the potential worldwide impact of its therapeutic candidates. Its research and therapies aim to address global health challenges in neurodegenerative diseases.

Street Address:

Wagistrasse 13

City:

Schlieren

State/Province:

Zurich

Country:

Switzerland

Where Else Does Neurimmune AG Operate Around the World?

No additional office locations available.

Buying Intent Signals for Neurimmune AG

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Neurimmune AG? Meet the Executive Team

As of April 2025, Neurimmune AG' leadership includes:

Prof. Dr. Roger M. Nitsch - Co-Founder, President & CEO
Prof. Dr. Christoph Hock - Co-Founder & CMO
Dr. Michael Salzmann - COO/CFO
Dr. Jan Grimm - CSO
Dr. Fabian Buller - CBO
Dr. John M. R. Misasi - Head of Preclinical Development & RTM Technology

Who's Investing in Neurimmune AG?

Neurimmune AG has been backed by several prominent investors over the years, including:

Privately Held Company
Biogen (Strategic Partner with significant financial commitments)
Ono Pharmaceutical (Strategic Partner with significant financial commitments)
TVM Capital Life Science (Early Investor)
Life Science Partners (LSP, now EQT Life Sciences) (Early Investor)

What Leadership Changes Has Neurimmune AG Seen Recently?

Hire0
Exits0

Based on publicly available information, there have been no major announced executive hires or exits at Neurimmune in the last 12-18 months, suggesting stability in the core leadership team. The company continues to build its broader team as programs advance.

What Technology (Tech Stack) Is Used byNeurimmune AG?

Discover the tools Neurimmune AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Neurimmune AG Email Formats and Examples

Neurimmune likely uses common corporate email formats. The most probable formats are [first_initial][last]@neurimmune.com or [first].[last]@neurimmune.com.

[first].[last]@neurimmune.com

Format

roger.nitsch@neurimmune.com

Example

85%

Success rate

What's the Latest News About Neurimmune AG?

neurimmune.com (Press Release)October 26, 2023

Neurimmune News: Neurimmune and Ono Pharmaceutical Enter into a Second Collaboration Agreement to Discover and Develop Novel Antibody Therapeutics for Neurodegenerative Diseases

Neurimmune and Ono Pharmaceutical Co., Ltd. announced they have entered into a second collaboration agreement to discover and develop novel antibody therapeutics for neurodegenerative diseases. This partnership will leverage Neurimmune's proprietary RTM™ Technology Platform to generate antibodies against new targets....more

globenewswire.com (Biogen Press Release)January 05, 2023

Neurimmune News: FDA Grants Accelerated Approval for LEQEMBI™ (lecanemab), co-developed with Biogen based on Neurimmune's technology

The U.S. Food and Drug Administration (FDA) granted accelerated approval for LEQEMBI™ (lecanemab-irmb), an Alzheimer's disease treatment. Lecanemab was developed by Eisai in partnership with Biogen, based on an antibody originally discovered through Neurimmune's RTM™ platform (antibody Bapineuzumab, further developed into Lecanemab). This marks a significant milestone for therapies derived from Neurimmune's foundational research....more

neurimmune.com (News)March 21, 2024

Neurimmune News: Neurimmune to Present New Preclinical Data on Novel Antibody Therapeutics for Parkinson’s Disease and ALS at AD/PD™ 2024 Conference

Neurimmune announced it would present new preclinical data on its antibody candidates for Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS) at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Neurimmune AG, are just a search away.